Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Leukemia, Myeloid, Acute 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 32Myelodysplastic Syndromes 27Multiple Myeloma 20Recurrence 19Lymphoma, Non-Hodgkin 15Lymphoma, B-Cell 14Lymphoma 14Leukemia, Lymphocytic, Chronic, B-Cell 13Ovarian Neoplasms 12Hematologic Neoplasms 12Melanoma 11Pancreatic Neoplasms 10Myeloproliferative Disorders 10Burkitt Lymphoma 10Leukemia 9Hodgkin Disease 9Stomach Neoplasms 8Lymphoma, Large B-Cell, Diffuse 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia, Biphenotypic, Acute 8Neoplasms 7Leukemia, Myelomonocytic, Chronic 7Colorectal Neoplasms 7Triple Negative Breast Neoplasms 6Osteosarcoma 6Neuroblastoma 6Neoplasm Metastasis 6Lymphoma, Mantle-Cell 6Lymphoma, Follicular 6

Interventions

fludarabine 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating × fludarabine × 90 days × Clear all
NCT07526493 2026-05-12

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Tongji Hospital

Phase 1 Recruiting
6 enrolled

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT07304154 2026-04-21

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Gilead Sciences

Phase 1 Recruiting
52 enrolled

Multiple Sclerosis, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡